Navigation Links
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
Date:2/21/2008

SOMERSET, N.J., Feb. 21 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that in vitro and in vivo data presented at the 5th Cancer Drug Research & Development conference show the genes affected and biological pathways impacted by ONCONASE stimulated intracellular events as revealed by expression profiling of human malignant mesothelioma cell lines. Data presented also show that ONCONASE conjugates effectively kill human cancer cells in cell culture and murine models of cancer.

Susanna Rybak, Ph.D., a member of Alfacell's scientific advisory board, presented a poster entitled "ONCONASE (ranpirnase): Intracellular Activity and Extracellular Selectivity." The data demonstrated that 181 genes were consistently up- and down-regulated by ONCONASE and that the genes involved in triggering apoptosis (programmed cell death) and the intracellular MAPK signaling pathway were impacted by ONCONASE in vitro. Additionally, pre-clinical data in mice demonstrated the relative potency of chemical conjugates of ONCONASE. These findings further support the research of next generation targeted ONCONASE fusion proteins in an effort to develop compounds with improved tumor penetrating abilities. The research was conducted in collaboration with Alfacell at Fox Chase Cancer Center and the University of Duisburg-Essen.

"This work may explain the intrinsic anti-tumor activity seen after ONCONASE treatment through the identification of the specific genes affected and the biological pathways impacted," said Dr. Rybak. "Additionally, this data is helping us to better understand the optimal intracellular pathways for developing antibody targeted ONCONASE compounds."

"The data presented further illuminates the potential for ONCONASE to simultaneously switch on and off numerous genes controlling major regulatory processes in the cell life cycle, and underscores that ONCONASE works selectively and does not appear to kill cells indiscriminately," added Kuslima Shogen, Alfacell's chief executive officer. "This research represents an important step forward in our continuing efforts to create targeted ONCONASE fusion proteins and to bring them forward into the clinic."

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of

ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media and Investor Contact:

David Schull or Wendy Lau

Russo Partners

212-845-4271

david.schull@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
5. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... physical therapy provider for Derby City CrossFit, effective immediately. , In addition to ... and effectively as possible, ProRehab’s sports physical therapists will work with athletes to ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are ... help with process innovation in drug formulation and manufacturing. CoreRx offers its ... analytical equipment in support of their development and manufacturing goals. , The ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing ... acute or chronic problems, I focus on preventative care with all my patients to alleviate ... any questions, always feel free to contact my office and my trained staff will assist ...
(Date:4/25/2017)... ... 2017 , ... Vetoquinol USA® , a world-class developer ... of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. ... level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage ...
Breaking Medicine News(10 mins):